Federal contract award
75A50123C00050
VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $45.2M |
| Current contract value | $45.2M |
| Potential contract value / ceiling | $191.9M |
| Start date | Sep 15, 2023 |
| Current end date | Dec 31, 2027 |
| Potential end date | Dec 31, 2029 |
| Latest award activity | Aug 4, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 4, 2026 | P00009 | $5.4M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0001 2. EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 (BASE) THROUGH DECEMBER 31, 2029 3. ADD ACTIVITIES UNDER CLIN0002 AT NO ADDITIONAL COST TO THE GOVERNMENT 4. REV |
| May 27, 2026 | P00008 | $13.3M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0002/OPTION 1, UPDATE THE PERIOD OF PERFORMANCE FOR CLIN0001/BASE THROUGH DECEMBER 31, 2027, AND SECTION J-ATTACHMENT 1 STATEMENT OF WORK DATED 3/26/2026. |
| Feb 24, 2026 | P00007 | $6.1M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0005/OPTION 4, UPDATE ARTICLES G.3 KEY PERSONNEL, G.4.G CONTRACT FINANCIAL REPORT, G.8 POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE, CPARS POINT OF CONTACT, AND SECTION J, ATTACHMENT 1 STATEMENT |
| Sep 24, 2025 | P00006 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO FINALIZE THE NOVATION AGREEMENT VIA THIS MODIFICATION THE UNITED STATES GOVERNMENT RECOGNIZES THAT ALL CONTRACTUAL OBLIGATIONS HAVE BEEN TRANSFERRED FROM VENATORX PHARMACEUTICALS, INC. TO BASILEA PHARMACEUTICA I |
| May 7, 2025 | P00005 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATES BASED ON DOCUMENTATION FROM NIH DATED APRIL 23, 2025, AND ARTICLE I.1 FAR 52.252-52, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998) IN ACCORDANCE WITH (I) FAR CL |
| Nov 25, 2024 | P00004 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES I.1 FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES, 52.204-14 SERVICES CONTRACT REPORTING REQUIREMENTS. |
| Jun 28, 2024 | P00003 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.1 CONTRACTING OFFICER, ARTICLE G.3 KEY PERSONNEL, AND UPDATE ATTACHMENT #1 - STATEMENT OF WORK DATED APRIL 25, 2024, BY REALIGNING WORK TO CORRESPONDING MILESTONES AT NO ADDITIONAL COST TO THE G |
| Jan 31, 2024 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATE |
| Nov 20, 2023 | P00001 | $0 | NO COST MODIFICATION TO UPDATE SECTION G.3 KEY PERONNEL |
| Sep 15, 2023 | 0 | $20.3M | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. |
Estimated positioning window
Dec 31, 2028 – Jun 30, 2029
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-12-31 (1156 days from calculation)
- +5 points
- 121 historical awards in this buyer and category group
- +15 points
- 10 recorded award transactions
- +10 points
- Latest award action: 2026-08-04
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.